Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P22362

UPID:
CCL1_HUMAN

ALTERNATIVE NAMES:
Small-inducible cytokine A1; T lymphocyte-secreted protein I-309

ALTERNATIVE UPACC:
P22362; B2R5G9; Q2M309

BACKGROUND:
The protein known as C-C motif chemokine 1, with alternative names Small-inducible cytokine A1 and T lymphocyte-secreted protein I-309, is distinguished by its chemotactic properties for monocytes, facilitated through binding to the CCR8 receptor. This selective chemotaxis highlights its critical function in the immune system, guiding monocytes to sites of inflammation or injury.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of C-C motif chemokine 1 offers a promising avenue for the development of novel therapeutic approaches. Its role in monocyte recruitment and potential implications in modulating immune responses provide a foundation for innovative treatments in managing inflammatory and immune-mediated conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.